| Amyotrophic Lateral Sclerosis
Tiglutik vs Qalsody
Side-by-side clinical, coverage, and cost comparison for amyotrophic lateral sclerosis.Deep comparison between: Tiglutik vs Qalsody with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQalsody has a higher rate of injection site reactions vs Tiglutik based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qalsody but not Tiglutik, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tiglutik
Qalsody
At A Glance
Oral
Every 12 hours
Benzothiazole
Intrathecal injection
Every 14 days (loading), then every 28 days
Antisense oligonucleotide
Indications
- Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis
Dosing
Amyotrophic Lateral Sclerosis 50 mg (10 mL) orally or via PEG-tube twice daily every 12 hours, taken at least 1 hour before or 2 hours after a meal.
Amyotrophic Lateral Sclerosis 100 mg (15 mL) intrathecally; 3 loading doses at 14-day intervals, then 100 mg every 28 days thereafter.
Contraindications
- History of severe hypersensitivity reactions to riluzole or to any of its components (anaphylaxis has occurred)
—
Adverse Reactions
Most common (>=5%) Asthenia, nausea, decreased lung function, hypertension, abdominal pain
Serious Hepatic injury, neutropenia, interstitial lung disease
Postmarketing Acute hepatitis, icteric toxic hepatitis, renal tubular impairment, pancreatitis
Most common (>=10%) Pain, fatigue, arthralgia, CSF white blood cell increased, myalgia
Serious Myelitis and/or radiculitis, papilledema and elevated intracranial pressure, aseptic meningitis
Pharmacology
The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown; its clinical pharmacodynamics have not been determined in humans.
Tofersen is an antisense oligonucleotide (ASO) that binds to SOD1 mRNA, causing its degradation and reducing SOD1 protein synthesis; it is not a substrate for, or inhibitor or inducer of, CYP450 enzymes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tiglutik
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Qalsody
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (4/12)
UnitedHealthcare
Tiglutik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Qalsody
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tiglutik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Qalsody
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/fillfill
Tiglutik Co-pay SupportCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Amyotrophic Lateral Sclerosis (ALS): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TiglutikView full Tiglutik profile
QalsodyView full Qalsody profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.